IP Library Granted Patent US 7,014,849
Granted Patent B1
US 7,014,849 · App. 10/031,188 · Granted Mar 21, 2006

Keratinocyte culture and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,014,849
App. No.
10/031,188
Granted
Mar 21, 2006
Kind
B1
Abstract

The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.

Claims (70)

1. A method for the treatment of a skin defect comprising

(a) culturing an intact hair follicle of an anagenic hair to obtain outer root sheath cells;

(b) culturing said outer root sheath cells to obtain keratinocyte precursor cells;

(c) preparing an epidermal or dermal equivalent comprising said keratinocyte precursor cells; and

(d) applying a portion of said epidermal or complex equivalent to said defect.

2. The method of claim 1 , wherein said outer root sheath cells are autologous cells obtained from an individual who will subsequently undergo treatment for a skin defect.

3. The method of claim 1 , wherein said outer root sheath cells are homologous cells.

4. The method of claim 1 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing only homologous or autologous biological supplements.

5. The method of claim 1 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing human serum in a concentration of less than 5%.

6. The method of claim 1 , wherein the culture density of said keratinocyte precursor cells is between about 3×10 4 cells/cm 2 and about 1×10 5 cells/cm 2 .

7. The method of claim 1 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a fibrin glue.

8. The method of claim 1 , wherein the graft thickness for said epidermal equivalents is 50–150 microns.

9. The method of claim 1 , wherein the graft thickness for said complex skin equivalents does not exceed 0.4 mm.

10. A method for the treatment of a skin defect comprising

(a) culturing an intact hair follicle of an anagenic hair to obtain outer root sheath cells;

(b) culturing said outer root sheath cells to obtain keratinocyte precursor cells;

(c) preparing an epidermal or dermal equivalent comprising said keratinocyte precursor cells; and

(d) applying a portion of said epidermal or complex skin equivalent to said defect

wherein all culturing of cells is performed in a medium which utilizes autologous or homologous human serum in a concentration of less than approximately 5%.

11. The method of claim 10 , wherein said anagen or growing hair is cultured in toto.

12. The method of claim 10 , wherein said outer root sheath cells are homologous cells.

13. The method of claim 10 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a fibrin glue.

14. The method of claim 10 , wherein the graft thickness for said epidermal equivalents is 50–150 microns.

15. The method of claim 10 , wherein the graft thickness for said complex skin equivalents does not exceed 0.4 mm.

16. A method for the treatment of a skin defect comprising

(a) culturing an intact hair follicle of an anagenic hair to obtain outer root sheath cells;

(b) culturing said outer root sheath cells to obtain keratinocyte precursor cells;

(c) preparing an epidermal or complex skin equivalent comprising said keratinocyte precursor cells; and

(d) applying a portion of said epidermal or complex skin equivalent to said defect

wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a fibrin glue.

17. The method of claim 16 , wherein said anagen or growing hair is cultured in toto.

18. The method of claim 16 , wherein said outer root sheath cells are autologous cells obtained from an individual who will subsequently undergo treatment for a skin defect.

19. The method of claim 16 , wherein said outer root sheath cells are homologous cells.

20. The method of claim 16 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing only homologous or autologous biological supplements.

21. The method of claim 16 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing human serum in a concentration of less than 5%.

22. The method of claim 16 , wherein the culture density of said keratinocyte precursor cells is between about 3×10 4 cells/cm 2 and about 1×10 5 cells/cm 2 .

23. The method of claim 16 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a fibrin glue which contains one or more anti-microbial, anti-fungal, or anti-viral agents emulsified therein.

24. A method for the selection of keratinocyte precursor cells from the outer root sheath of hair for subsequent use in a composition for healing a skin defect, comprising the steps of:

(a) plucking of an intact anagen hair;

(b) primary-culturing the outer root sheath-derived keratinocyte precursor cells by adhering said intact anagen hair to a microporous membrane, which possesses growth-arrested/limited feeder cells on its undersurface so as to select for keratinocyte precursor cells from the outer root sheath of hair;

(c) organotypically-culturing the outer root sheath cells harvested from said primary cultures by inoculating a microporous membrane which also possesses growth-arrested/limited feeder cells on its undersurface;

(d) generating an epidermal or complex skin equivalent, for subsequent use as a graft insert, by placing a carrier membrane on top of said organotypic-culture from step

(c) and detaching said complex skin or epidermal equivalent, which is comprised of the keratinocyte precursor cells and carrier membrane, together as a single, laminar unit;

(e) contacting said epidermal or complex skin equivalent with a skin defect present on an individual, and immobilizing said epidermal or skin equivalent at the site of contact.

25. The method of claim 24 , wherein said outer root sheath cells are autologous cells derived from the individual who will subsequently undergo treatment for a skin defect.

26. The method of claim 24 , wherein said outer root sheath cells are homologous cells.

27. The method of claim 24 , wherein the culture density of said keratinocyte precursor cells is between about 3×10 4 cells/cm 2 and about 1×10 5 cells/cm 2 .

28. The method of claim 24 , wherein the culture density of said growth-arrested/limited feeder cells on said microporous membrane is between about 1×10 4 cells/cm 2 and about 5×10 4 cells/cm 2 .

29. The method of claim 24 , wherein said growth-arrested/limited feeder cells are banked or immortalized cells.

30. The method of claim 24 , wherein said primary and organotypic cultures utilize autologous or homologous human serum.

31. The method of claims 24 , wherein said primary and organotypic cultures utilize autologous or homologous human serum in a concentration of less than about 5%.

32. The method of claim 24 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing only homologous or autologous biological supplements.

33. The method of claim 24 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing only homologous or autologous releasates from blood components.

34. The method of claims 24 , wherein said epidermal or complex skin equivalent comprises outer root sheath cells cultured in a medium containing only homologous or autologous releasates from blood components at a concentration of about 0.1% to about 20%.

35. The method of claim 24 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a fibrin glue.

36. The method of claims 24 , wherein the graft thickness for said epidermal equivalents is 50–150 microns.

37. The method of claims 24 , wherein the graft thickness for said complex skin equivalents does not exceed 0.4 mm.

38. The method of claim 24 , wherein said microporous membrane is coated by one or ore extracellular matrix substances selected from a group consisting of: fibrin, fibronectin, collagens, laminins and hyaluronan.

39. The method of claims 24 , wherein said microporous membrane possesses a growth-arrested/limited feeder cell system on its undersurface with said feeder cells of at least one type of cell selected from the group comprising human dermal fibroblasts, epidermal cells, mesenchymal cells, neuronal cells and endothelial cells.

40. The method of claim 24 , wherein said carrier membrane is made from one or more types of materials selected from the group comprising polyester, PTFE, polyurethane, hyaluronic acid, polylactic acid, collagen, or a silicone or vaseline gauze dressing.

41. The method of claim 24 , wherein the size of said epidermal equivalent is selected from the group consisting of 1.0 cm, 1.5 cm, 2.0 cm, and 2.5 cm in diameter.

42. A method of shipping or transporting epidermal equivalents prepared according to the method of claim 1 comprising:

(a) detaching said epidermal equivalents from a culture medium, and

(b) transferring said epidermal equivalents onto a transport medium.

43. The method of claim 42 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a fibrin glue.

44. The method of claim 43 , wherein said epidermal equivalents are further sealed and shipped for future use in grafting.

45. The method of claim 42 , wherein said transport medium comprises a solidified or gelled medium.

46. The method of claim 45 , wherein said solidified or gelled medium is selected from the group consisting of agarose, methyl cellulose, or another gelifying substance.

47. The method of claim 10 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a carrier membrane.

48. The method of claim 22 , wherein said epidermal or complex skin equivalent is coated on its top or cornified side with a carrier membrane.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2013
From: HEALTHPOINT INTERNATIONAL, LLC
To: SMITH & NEPHEW, INC.
Reel/Frame 029994/0633 →
CHANGE OF NAME Recorded Dec 17, 2012
From: DFB TECHNOLOGY HOLDINGS, LLC; HEALTHPOINT HOLDINGS, LLC
To: HEALTHPOINT INTERNATIONAL, LLC
Reel/Frame 029481/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2010
From: DFB PHARMACEUTICALS, INC.
To: DFB TECHNOLOGY HOLDINGS, LLC
Reel/Frame 023788/0443 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNOR FROM 'EPITECH SA' TO --EPISOURCE SA--. PREVIOUSLY RECORDED ON REEL 016862 FRAME 0490. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE AND INTEREST FOR THE UNITED STATES AND IN ALL COUNTRIES.. Recorded Sep 21, 2007
From: EPISOURCE SA
To: DFB PHARMACEUTICALS, INC.
Reel/Frame 019864/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2005
From: EPITECH SA
To: DFB PHARMACEUTICALS, INC.
Reel/Frame 016862/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2004
From: MODEX THERAPEUTIQUES SA (NOW KNOWN AS ISOTIS SA)
To: EPISOURCE SA
Reel/Frame 015409/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2004
From: EPITECH SA
To: MODEX THERAPEUTIQUES SA (NOW ISOTIS SA)
Reel/Frame 015312/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2002
From: HUNZIKER, THOMAS; LIMAT, ALAIN
To: EPITECH, S.A.
Reel/Frame 012918/0875 →